ForteBio is now part of the Sartorius group. Click here for more

Resources Search

Filter By:

Search Results

Results 51 - 60 of 835

A rapid method to quantitatively screen bispecific antibody using Protein A and His1K biosensors

Bispecific antibodies (bsAbs) were first reported by Nisonoff and Rivers in 19611 , however the engineering challenges associated with bsAbs have limited their development. Recent advances in…


Validated Quantitation and Activity Assay of Antibody Fragment Molecule (Fab) for Process Development and Quality Control

The group was able to develop a working Fab activity assay on the Octet RED system in less than a week. Relative to the overnight incubation and four-hour assay time of their ELISA protocol, the…


OneStep Lead Characterization of High Affinity Biologic Interactions with Pioneer SPR Systems

Biopharmaceutical drug discovery and development have celebrated the approval of breakthrough treatments in diseases of inflammation, cancer and infectious disease in recent years.


Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs.


Commitment to Covalency : Kinetics of Irreversible Inhibitors on the Pioneer FE System

The principal role of assay groups in drug discovery is to provide reliable methods, analysis, and data for confident decision-making about series progression. Particular assays are chosen to…


We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.